Summary of findings for the main comparison. One week of AmBd + 5FC compared to two weeks of AmBd + 5FC for HIV‐associated cryptococcal meningitis.
| One week of AmBd + 5FC compared to two weeks of AmBd + 5FC for HIV‐associated cryptococcal meningitis | |||||
| Patient or population: HIV‐infected individual with first episode of cryptococcal meningitis Setting: randomized controlled trial Intervention: 1 week of AmBd + 5FC Comparison: 2 weeks of AmBd + 5FC | |||||
| Outcomes | Anticipated absolute effects* (95% CI) | Relative effect (95% CI) | Number of participants (trials) | Certainty of the evidence (GRADE) | |
| Risk with 2 weeks of AmBd + 5FC | Risk with 1 week of AmBd + 5FC | ||||
| Mortality: 10 weeks | 383 per 1000 | 237 per 1000 (161 to 356) | RR 0.62 (0.42 to 0.93) | 228 (1 RCT) | ⊕⊕⊕⊝ MODERATE1 |
| *The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). Abbreviations: 5FC: flucytosine; AmBd: amphotericin B deoxycholate; CI: confidence interval; RCT: randomized controlled trial; RR: risk ratio | |||||
| GRADE Working Group grades of evidence High certainty: we are very confident that the true effect lies close to that of the estimate of the effect. Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. | |||||
1Downgraded one level for imprecision. Data from a single study with few events.